FDG and Beyond

Ruysscher, Dirk De; Haustermans, Karin; Thorwarth, Daniela

doi:10.1007/978-3-662-49651-0_8

Cited by 6 publications

(10 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it becomes clear, that many of the (comparatively newly installed) cyclotrons have a proton beam of up to 18 MeV. With regard to the production of radionuclides for patient care, 18 MeV are ideally suited to produce the most common radionuclides for PET imaging such as 18 F, 11 C, 64 Cu, 68 Ga and 89 Zr. Systems with higher beam energies, which enable the production of further SPECT and therapeutic radionuclides like 123 I and 67 Cu [e.g., the Jülich Cyclone R 30 XP (39)], on the other hand, were installed less often or even decommissioned.…”

Section: Development Current Status and Trendsmentioning

confidence: 99%

“…The result is radioactive atoms that can be separated from the target material and radiochemically processed in synthesis modules (radiosynthesizers) for the automated production of tracers, which are formulated mainly into saline PET radiopharmaceutical injection solutions to image patients by intravenous injection of the radiopharmaceutical (15,16). Common short-lived radionuclides used for PET imaging include e.g., 18 F, 68 Ga, 11 C, 13 N, 15 O, 44 Sc, 64 Cu, 89 Zr, 86 Y and 124 I (9,(17)(18)(19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends

Zippel¹,

Ermert

Patt

et al. 2022

Front. Nucl. Med.

View full text Add to dashboard Cite

BackgroundCyclotrons form a central infrastructure and are a resource of medical radionuclides for the development of new radiotracers as well as the production and supply of clinically established radiopharmaceuticals for patient care in nuclear medicine.AimTo provide an updated overview of the number and characteristics of cyclotrons that are currently in use within radiopharmaceutical sciences and for the development of radiopharmaceuticals to be used for patient care in Nuclear Medicine in Germany (D), Austria (A) and Switzerland (CH).MethodsPublicly available information on the cyclotron infrastructure was (i) consolidated and updated, (ii) supplemented by selective desktop research and, last but not least, (iii) validated by members of the committee of the academic “Working Group Radiochemistry and Radiopharmacy” (AGRR), consisting of radiochemists and radiopharmacists of the D-A-CH countries and belonging to the German Society of Nuclear Medicine (DGN), as well as the Radiopharmaceuticals Committee of the DGN.ResultsIn total, 42 cyclotrons were identified that are currently being operated for medical radionuclide production for imaging and therapy in Nuclear Medicine clinics, 32 of them in Germany, 4 in Austria and 6 in Switzerland. Two thirds of the cyclotrons reported (67%) are operated by universities, university hospitals or research institutions close to a university hospital, less by/in cooperation with industrial partners (29%) or a non-academic clinic/ PET-center (5%). Most of the cyclotrons (88%) are running with up to 18 MeV proton beams, which is sufficient for the production of the currently most common cyclotron-based radionuclides for PET imaging.DiscussionThe data presented provide an academically-updated overview of the medical cyclotrons operated for the production of radiopharmaceuticals and their use in Nuclear Medicine in the D-A-CH countries. In this context, we discuss current developments and trends with a view to the cyclotron infrastructure in these countries, with a specific focus on organizational aspects.

show abstract

Section: Development Current Status and Trendsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends

Zippel¹,

Ermert

Patt

et al. 2022

Front. Nucl. Med.

View full text Add to dashboard Cite

show abstract

“…Hybrid imaging modalities, including PET/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MRI), are currently available and may allow to combine functional and morphological information on cancer patients. Different PET radiotracers evaluating different metabolic pathways or receptor statuses may be used in this setting [ 1 , 2 , 3 , 4 ]. Although many PET radiotracers are currently available, fluorine-18 fluorodeoxyglucose ([ 18 F]F-FDG) is still the most widely used PET radiotracer in oncology [ 2 , 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…Different PET radiotracers evaluating different metabolic pathways or receptor statuses may be used in this setting [ 1 , 2 , 3 , 4 ]. Although many PET radiotracers are currently available, fluorine-18 fluorodeoxyglucose ([ 18 F]F-FDG) is still the most widely used PET radiotracer in oncology [ 2 , 3 , 4 ]. [ 18 F]F-FDG uptake is related to glucose metabolism, and increased glucose metabolism is one of the hallmarks of many cancer types.…”

Section: Introductionmentioning

confidence: 99%

“…[ 18 F]F-FDG uptake is related to glucose metabolism, and increased glucose metabolism is one of the hallmarks of many cancer types. However, [ 18 F]F-FDG has known limitations, such as its high physiological uptake in many normal tissues (hampering the detection of tumor lesions in these sites), its low uptake in certain tumor types (as several well-differentiated tumors), and a lack of specificity (as several diseases may be characterized by increasing glucose metabolism); these limitations represent the basis for the continuous development of new PET radiotracers in oncology [ 2 , 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F]F-FDG in Oncology: A Systematic Review

Treglia

Muoio

Roustaei

et al. 2021

IJMS

View full text Add to dashboard Cite

Several recent studies comparing radiolabeled fibroblast activation protein inhibitors (FAPI) and fluorine-18 fluorodeoxyglucose ([18F]F-FDG) as positron emission tomography (PET) radiotracers in oncology have been published. The aim of this systematic review is to perform an updated evidence-based summary about the comparison of these PET radiotracers in oncology to better address further research in this setting. Studies or subsets of studies comparing radiolabeled FAPI and [18F]F-FDG as PET radiotracers in oncology were eligible for inclusion in this systematic review. A systematic literature search of PubMed/MEDLINE and Cochrane library databases was performed until August 2021. Literature data about the comparison of [18F]F-FDG and radiolabeled FAPI are rapidly increasing. Overall, taking into account radiotracer uptake and tumor-to-background uptake ratio, compared to [18F]F-FDG PET, an equal or higher detection of primary tumors and/or metastatic lesions was usually demonstrated by using radiolabeled FAPI PET. In particular, the cancer entities with better detection rate of tumor lesions by using radiolabeled FAPI PET, compared to [18F]F-FDG PET, were gastrointestinal tumors, liver tumors, breast cancer and nasopharyngeal carcinoma. Further comparison studies are needed to better evaluate the best field of application of radiolabeled FAPI PET.

show abstract